FSHR and ovarian carcinoma: This ligand recognizes the FSH receptor overexpressed in ovarian cancer cells, favoring nanoparticle–cell interaction and facilitating entry into the cells, possibly by receptor-mediated endocytosis and its consequent selective internalization, as previously reported [20].